Atara Biotherapeutics Q1 Revenue Plummets 82% Below Estimates, Reports Net Loss
ATRA has more than doubled off its 52-week low of $3.92.
Summary
Atara Biotherapeutics reported a significant Q1 revenue miss, coming in at $516,000 against a consensus estimate of $2.85 million, an 82% shortfall. The company also posted a net loss of $4.15 million, reversing a prior-year profit. While the revenue decline was partly attributed to a one-time gain in the prior year from a manufacturing transfer, the current quarter's performance is weak. Positively, operating expenses declined significantly due to 2025 cost-reduction initiatives, extending the company's cash runway into mid-2027. This financial update is critical for investors, especially following the recent Nasdaq delisting notice and the company's prior 'going concern' warning, providing a mixed but overall challenging financial picture.
At the time of this announcement, ATRA was trading at $9.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.5M. The 52-week trading range was $3.92 to $19.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.